CloudCath

CloudCath is a private, commercial-stage company focused on transforming home-based peritoneal dialysis care through its remote patient monitoring platform. Its core technology objectively quantifies dialysis fluid turbidity, identifying signs of peritonitis an average of 3.1 days earlier than patient-reported symptoms, as validated in a 2024 clinical study. This early detection has demonstrated significant clinical outcomes, including a 45% reduction in hospitalization and a 56% reduction in catheter loss, potentially improving patient retention on PD therapy. The company targets a critical need in the growing home dialysis market by providing data-driven tools for clinicians and patients.

Hardware add-on for PD cyclers that uses optical sensing to quantify dialysis fluid turbidity, coupled with cloud-based analytics and proprietary algorithms for differential particle analysis and early infection detection.

CloudCath appears to be a first-mover in automated, continuous remote monitoring of PD effluent for infection. Direct competitors are not yet prominent, but the primary competition is the entrenched, subjective standard of care (visual inspection). Long-term competitive threats could come from PD machine manufacturers integrating similar monitoring capabilities directly into next-generation cyclers.